Patents by Inventor Jerry Peterson
Jerry Peterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240160838Abstract: A method for enabling a user to select and interact with text, lines, or paragraphs of a document, in the case where the document is available as a PDF or image. Embodiments enable the representation of a document to go beyond simple extraction of text, including organizing the text into logical groups of benefit to a user, such as paragraph, header, footer, or table (as examples), and labelling them as such. This facilitates subsequent processing, including application of machine learning (ML) algorithms to leverage this explicit information.Type: ApplicationFiled: November 13, 2023Publication date: May 16, 2024Inventors: Amine Anoun, Andrew Johnson, Jacob Sussman, Jerry Ting, Riley Hawkins, Derek Peterson
-
Publication number: 20090010848Abstract: The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen. Such humanization enables the use of these antibodies for immunodiagnostic and immunotherapeutic applications in humans.Type: ApplicationFiled: June 20, 2008Publication date: January 8, 2009Inventors: Fernando J.R. do Couto, Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 7390635Abstract: The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen. Such humanization enables the use of these antibodies for immunodiagnostic and immunotherapeutic applications in humans.Type: GrantFiled: October 13, 2004Date of Patent: June 24, 2008Assignee: Cancer Research Institute of Contra CostaInventors: Fernando J. R. Do Couto, Robert L. Ceriani, Jerry A. Peterson
-
Publication number: 20060216303Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: ApplicationFiled: June 23, 2004Publication date: September 28, 2006Inventors: Fernando do Couto, Roberto Ceriani, Jerry Peterson, Eduardo Padlan
-
Patent number: 6936706Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: GrantFiled: September 6, 2001Date of Patent: August 30, 2005Inventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson, Eduardo A. Padlan
-
Publication number: 20050169915Abstract: The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen. Such humanization enables the use of these antibodies for immunodiagnostic and immunotherapeutic applications in humans.Type: ApplicationFiled: October 13, 2004Publication date: August 4, 2005Inventors: Fernando Do Couto, Roberto Ceriani, Jerry Peterson
-
Publication number: 20030138428Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: ApplicationFiled: September 6, 2001Publication date: July 24, 2003Inventors: Fernando J.R. do Couto, Roberto L. Ceriani, Jerry A. Peterson, Eduardo A. Padlan
-
Publication number: 20020164339Abstract: The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer.Type: ApplicationFiled: September 17, 2001Publication date: November 7, 2002Inventors: Fernando J.R. do Couto, Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 6315997Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: GrantFiled: November 21, 1997Date of Patent: November 13, 2001Assignee: Cancer Research FundInventors: Fernando J.R. do Couto, Roberto L. Ceriani, Jerry A. Peterson, Eduardo A. Padlan
-
Patent number: 6309636Abstract: The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. The present invention also provides methods for the humanization of antibodies such as murine monoclonal antibodies. The novel humanization methods are applied to the production of humanized Mc3 antibodies and it is shown that these humanized antibodies retain the ability to engage in high affinity binding to their cognate antigen. Such humanization enables the use of these antibodies for immunodiagnostic and immunotherapeutic applications in humans.Type: GrantFiled: September 14, 1995Date of Patent: October 30, 2001Assignee: Cancer Research Institute of Contra CostaInventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 6190885Abstract: A fusion protein comprises a sequence of amino acids which binds antibodies specific to the human milk fat globule (HMFG) differentiation antigens. Specific amino acid sequences are provided, and a fusion protein may be used as an immunogen and for diagnostic purposes.Type: GrantFiled: October 8, 1993Date of Patent: February 20, 2001Assignee: Cancer Research Fund of Contra CostaInventors: Roberto L. Ceriani, Jerry A. Peterson, David J. Larocca
-
Patent number: 5972337Abstract: A polypeptide has the antibody binding activity of the 46 Kdalton HMFG antigen and/or homology to at least one of the light chains of clotting factors V and VIII and/or contains RGD and/or EGF-like segments. The polypeptide is provided as a recombinant and/or glycosylated and/or fusion protein. An antibody has high affinity for specificity epitopes of the polypeptide of the invention. Polynucleotide segments encode the polypeptide, recombinant and fusion protein of the invention or fragments thereof, and immunoassay kits comprise the antibodies and/or polypeptides of the invention and other components. In vivo, ex vivo, and in vitro methods of therapy, vaccination and diagnosis utilize the polypeptide, fusion protein anti-sense nucleotides, antibodies or and polynucleotides of the invention.Type: GrantFiled: December 3, 1993Date of Patent: October 26, 1999Assignee: Cancer Research Fund of Contra CostaInventors: Robeto L. Ceriani, Jerry A. Peterson, David J. Larocca
-
Patent number: 5804187Abstract: An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid.Type: GrantFiled: September 30, 1993Date of Patent: September 8, 1998Assignee: Cancer Research Fund of Contra CostaInventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 5792852Abstract: A polynucleotide encodes a modified antibody, or single chains thereof. The modified antibody has a non-antigen-binding peptide such as the constant regions of an antibody of a first species, peptide hormones, enzymes, and peptide transmitters; and a binding peptide such as the unsubstituted light and heavy chains of the variable region of an antibody of a second species which binds the human milk fat globule (HMFG) antigen. The non-antigen-binding peptide is linked to at least one chain of the binding peptide, the chains may be linked to one another at a site other than the antigenic binding site, and at least one chain of the binding peptide has 1 to 46 amino acids substituted with amino acids selected from specific ones assigned to each site. The polynucleotide and other products are also provided in the form of compositions, with a carrier.Type: GrantFiled: November 16, 1992Date of Patent: August 11, 1998Assignee: Cancer Research Fund of Contra CostaInventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson, Eduardo A. Padlan
-
Patent number: 5766571Abstract: An improved in vivo method of inhibiting or retarding the growth of malignant tumor cells in a subject comprises administering the subject antitumor therapy, the improvement comprising administering to the subject at least one product comprising an agent selected from the group consisting of polyunsaturated fatty acids, prostaglandins, prostacyclins, thromboxanes, leukotrienes, malone-aldehyde, triene epoxides, analogs thereof, salts thereof and mixtures thereof, the antitumor therapy and the product being administered in amounts and for a period of time effective to attain the desired effect.Type: GrantFiled: June 29, 1995Date of Patent: June 16, 1998Assignee: Cancer Research Fund of Contra CostaInventors: Roberto L. Ceriani, Jerry A. Peterson
-
Patent number: 5667797Abstract: An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, skim milk, curd, whey, the milk mucin complex, the 46 Kd app.MW glycoprotein, a polypeptide having an amino acid sequence having the rotavirus binding specificity of the 46 Kd app.MW HMFG glycoprotein or mixtures thereof. An anti-diarrheal kit comprises the anti-rotaviral agent of this invention and instructions for its use, and optionally a foodstuff. A method for inhibiting or countering rotavirus infection in mammalian cells comprises contacting the cells with an anti-rotaviral amount of the agent of this invention.Type: GrantFiled: April 1, 1996Date of Patent: September 16, 1997Assignees: Cancer Research Fund of Contra Costa, Senomed, Inc., The Johns Hopkins University School of MedicineInventors: Jerry A. Peterson, David S. Newburg, Robert H. Yolken
-
Patent number: 5536647Abstract: A polypeptide has the antibody binding activity of the 70K dalton HMFG differentiation antigen and is also provided as a fusion protein with a second antigenic polypeptide. An antibody has affinity for the polypeptide of the invention or a functional fragment thereof. in vivo and in vitro methods for therapy, vaccination and detecting the presence of the polypeptide, the antibody, the DNA and RNA of the invention are provided. DNA and RNA sequences encode the polypeptide of the invention or fragments thereof and immunoassay kits comprise the antibodies and/or polypeptides of the invention.Type: GrantFiled: July 25, 1994Date of Patent: July 16, 1996Assignee: Cancer Research Fund of Contra CostaInventors: Roberto L. Ceriani, Jerry A. Peterson, David J. Larocca
-
Patent number: 5532135Abstract: An in vitro solid-phase, competitive assay for detecting the presence of a peptide analyte in a biological sample comprises contacting a fusion protein, of first and second peptides, with a solid supported first antibody or fragment thereof, which binds the first peptide, adding a biological sample containing the peptide analyte and a second antibody or fragment thereof which binds the peptide analyte and the second peptide. The second antibody is allowed to bind any free analyte present in the sample, and to form solid supported complexes of fusion protein and antibody. The amount of solid supported second antibody detected is then compared to a control. When the amount of peptide analyte in the sample increases the amount of second antibody bound to the solid support decreases. An optional final addition of an antibody-binding molecule helps detect the solid supported complexes of the fusion protein and the second antibody or fragment.Type: GrantFiled: April 8, 1993Date of Patent: July 2, 1996Assignee: Cancer Research Fund of Contra CostaInventors: Roberto L. Ceriani, Jerry A. Peterson, David J. Larocca
-
Patent number: 5514558Abstract: An in vitro solid-phase, competitive assay for detecting the presence of a peptide analyte in a biological sample, comprising contacting a fusion protein made of a first peptide and a second peptide to a solid supported first antibody which specifically binds to the first peptide, adding thereto a biological sample containing a peptide analyte, adding a second antibody specifically binding to the analyte and the second peptide, and allowing the second antibody to bind any free analyte present in the sample and the solid supported fusion protein to form analyte-second antibody and solid supported fusion protein-second antibody complexes, and determining the amount of solid supported second antibody present and comparing it to a control. When the amount of peptide analyte in the sample increases the amount of a second antibody bound to the solid support decreases. An optional final addition of an antibody-binding molecule helps detect the antibody-fusion protein complex bound to the solid support.Type: GrantFiled: September 30, 1993Date of Patent: May 7, 1996Assignee: Cancer Research Fund of Contra CostaInventors: Roberto L. Ceriani, Jerry A. Peterson, David J. Larocca
-
Patent number: RE40535Abstract: An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with amino acid present in equivalent positions in antibodies of a species other than munne, and the constant regions of a human antibody. The antibody may be labeled and/or glycosylated, and is presented as a composition with a carrier. The anti-KC-4 monoclonal antibody is used in diagnostic kits for cancer and in in vivo methods of imaging and treating a primary or metastasized cancer, and in vitro diagnosis and ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the monoclonal antibody, and a hybrid vector carrying the nucleotides and transfected cells express the peptides.Type: GrantFiled: May 14, 2002Date of Patent: October 7, 2008Assignee: IBC Pharmaceuticals, Inc.Inventors: Fernando J. R. do Couto, Roberto L. Ceriani, Jerry A. Peterson